Doliprane paediatric recall: high-salience safety story in France, but the packet gives you no ticker
The Opportunity
The underlying claim is specific and consumer-salient: a recall of multiple lots of Doliprane 2.4% paediatric oral suspension in France tied to a dosing pipette defect (graduations fading), with an overdose-risk framing. 7A resolves this SHORT (48% conviction) because recalls create immediate operational and reputational pressure. In practice, the equity impact depends entirely on who owns the brand, who manufactured, and whether this is isolated or symptomatic.
The Timing
This stays AVOID because the mapping is missing: no issuer, no proxy, no instrument. Macro regime is Mixed 58 with Headwind 17 for shorts. What would change the assessment is an official ANSM notice plus a manufacturer statement that names the MAH/manufacturer and scope, or evidence of repeated packaging QC failures that escalate into a broader quality narrative.
The Evidence
The hydrated artefact is a French-language media write-up describing the recall mechanics and distribution window. Source: letempstg.com .